Literature DB >> 22920187

Generation and characterization of non-competitive furin-inhibiting nanobodies.

Jingjing Zhu1, Jeroen Declercq, Bart Roucourt, Gholamreza H Ghassabeh, Sandra Meulemans, Jörg Kinne, Guido David, Alphons J M Vermorken, Wim J M Van de Ven, Iris Lindberg, Serge Muyldermans, John W M Creemers.   

Abstract

The PC (proprotein convertase) furin cleaves a large variety of proproteins and hence plays a major role in many pathologies. Therefore furin inhibition might be a good strategy for therapeutic intervention, and several furin inhibitors have been generated, although none are entirely furin-specific. To reduce potential side effects caused by cross-reactivity with other proteases, dromedary heavy-chain-derived nanobodies against catalytically active furin were developed as specific furin inhibitors. The nanobodies bound only to furin but not to other PCs. Upon overexpression in cell lines, they inhibited the cleavage of two different furin substrates, TGFβ (transforming growth factor β) and GPC3 (glypican 3). Purified nanobodies could inhibit the cleavage of diphtheria toxin into its enzymatically active A fragment, but did not inhibit cleavage of a small synthetic peptide-based substrate, suggesting a mode-of-action based on steric hindrance. The dissociation constant of purified nanobody 14 is in the nanomolar range. The nanobodies were non-competitive inhibitors with an inhibitory constant in the micromolar range as demonstrated by Dixon plot. Furthermore, anti-furin nanobodies could protect HEK (human embryonic kidney)-293T cells from diphtheria-toxin-induced cytotoxicity as efficiently as the PC inhibitor nona-D-arginine. In conclusion, these antibody-based single-domain nanobodies represent the first generation of highly specific non-competitive furin inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22920187      PMCID: PMC4737579          DOI: 10.1042/BJ20120537

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  52 in total

1.  MMTV-cre-mediated fur inactivation concomitant with PLAG1 proto-oncogene activation delays salivary gland tumorigenesis in mice.

Authors:  Lieselot De Vos; Jeroen Declercq; Georgina Galicia Rosas; Boudewijn Van Damme; Anton Roebroek; Fons Vermorken; Jan Ceuppens; Wim van de Ven; John Creemers
Journal:  Int J Oncol       Date:  2008-05       Impact factor: 5.650

2.  Potent enzyme inhibitors derived from dromedary heavy-chain antibodies.

Authors:  M Lauwereys; M Arbabi Ghahroudi; A Desmyter; J Kinne; W Hölzer; E De Genst; L Wyns; S Muyldermans
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

3.  Pro-protein convertase gene expression in human breast cancer.

Authors:  M Cheng; P H Watson; J A Paterson; N Seidah; M Chrétien; R P Shiu
Journal:  Int J Cancer       Date:  1997-06-11       Impact factor: 7.396

4.  Processing of the Ebola virus glycoprotein by the proprotein convertase furin.

Authors:  V E Volchkov; H Feldmann; V A Volchkova; H D Klenk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

5.  Intracellular processing of complement pro-C3 and proalbumin is inhibited by rat alpha 1-protease inhibitor variant (Met352----Arg) in transfected cells.

Authors:  Y Misumi; K Ohkubo; M Sohda; N Takami; K Oda; Y Ikehara
Journal:  Biochem Biophys Res Commun       Date:  1990-08-31       Impact factor: 3.575

6.  Elevated furin expression in aggressive human head and neck tumors and tumor cell lines.

Authors:  D E Bassi; H Mahloogi; L Al-Saleem; R Lopez De Cicco; J A Ridge; A J Klein-Szanto
Journal:  Mol Carcinog       Date:  2001-08       Impact factor: 4.784

7.  Agouti-related protein is posttranslationally cleaved by proprotein convertase 1 to generate agouti-related protein (AGRP)83-132: interaction between AGRP83-132 and melanocortin receptors cannot be influenced by syndecan-3.

Authors:  John W M Creemers; Lynn E Pritchard; Amy Gyte; Philippe Le Rouzic; Sandra Meulemans; Sharon L Wardlaw; Xiaorong Zhu; Donald F Steiner; Nicola Davies; Duncan Armstrong; Catherine B Lawrence; Simon M Luckman; Catherine A Schmitz; Rick A Davies; John C Brennand; Anne White
Journal:  Endocrinology       Date:  2005-12-29       Impact factor: 4.736

8.  Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity.

Authors:  Stefan Henrich; Iris Lindberg; Wolfram Bode; Manuel E Than
Journal:  J Mol Biol       Date:  2005-01-14       Impact factor: 5.469

9.  Limited redundancy of the proprotein convertase furin in mouse liver.

Authors:  Anton J M Roebroek; Neil A Taylor; Els Louagie; Ilse Pauli; Liesbeth Smeijers; An Snellinx; Annick Lauwers; Wim J M Van de Ven; Dieter Hartmann; John W M Creemers
Journal:  J Biol Chem       Date:  2004-10-07       Impact factor: 5.157

10.  The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo.

Authors:  Miroslav S Sarac; Angus Cameron; Iris Lindberg
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.609

View more
  13 in total

1.  Interactions between metal-binding domains modulate intracellular targeting of Cu(I)-ATPase ATP7B, as revealed by nanobody binding.

Authors:  Yiping Huang; Sergiy Nokhrin; Gholamreza Hassanzadeh-Ghassabeh; Corey H Yu; Haojun Yang; Amanda N Barry; Marco Tonelli; John L Markley; Serge Muyldermans; Oleg Y Dmitriev; Svetlana Lutsenko
Journal:  J Biol Chem       Date:  2014-09-24       Impact factor: 5.157

2.  Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism.

Authors:  Sven O Dahms; Marcelino Arciniega; Torsten Steinmetzer; Robert Huber; Manuel E Than
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-19       Impact factor: 11.205

Review 3.  Proprotein convertase inhibition: Paralyzing the cell's master switches.

Authors:  Andres J Klein-Szanto; Daniel E Bassi
Journal:  Biochem Pharmacol       Date:  2017-04-27       Impact factor: 5.858

Review 4.  The proprotein convertase furin in cancer: more than an oncogene.

Authors:  Abdel-Majid Khatib; John W M Creemers; Zongsheng He
Journal:  Oncogene       Date:  2022-01-07       Impact factor: 8.756

5.  Nanobody-based binding assay for the discovery of potent inhibitors of CFTR inhibitory factor (Cif).

Authors:  Natalia Vasylieva; Seiya Kitamura; Jiexian Dong; Bogdan Barnych; Kelli L Hvorecny; Dean R Madden; Shirley J Gee; Dennis W Wolan; Christophe Morisseau; Bruce D Hammock
Journal:  Anal Chim Acta       Date:  2019-01-09       Impact factor: 6.558

6.  Liver-Specific Inactivation of the Proprotein Convertase FURIN Leads to Increased Hepatocellular Carcinoma Growth.

Authors:  Jeroen Declercq; Bas Brouwers; Vincent P E G Pruniau; Pieter Stijnen; Krizia Tuand; Sandra Meulemans; Annik Prat; Nabil G Seidah; Abdel-Majid Khatib; John W M Creemers
Journal:  Biomed Res Int       Date:  2015-06-08       Impact factor: 3.411

7.  Single Nucleotide Polymorphism (rs4932178) in the P1 Promoter of FURIN Is Not Prognostic to Colon Cancer.

Authors:  Jeroen Declercq; Bart Jacobs; Bart Biesmans; Arnaud Roth; Dirk Klingbiel; Sabine Tejpar; John W Creemers
Journal:  Biomed Res Int       Date:  2015-06-07       Impact factor: 3.411

Review 8.  Why All the Fury over Furin?

Authors:  Essam Eldin A Osman; Alnawaz Rehemtulla; Nouri Neamati
Journal:  J Med Chem       Date:  2021-08-02       Impact factor: 7.446

9.  X-ray structures of human furin in complex with competitive inhibitors.

Authors:  Sven O Dahms; Kornelia Hardes; Gero L Becker; Torsten Steinmetzer; Hans Brandstetter; Manuel E Than
Journal:  ACS Chem Biol       Date:  2014-04-01       Impact factor: 5.100

10.  The structure of a furin-antibody complex explains non-competitive inhibition by steric exclusion of substrate conformers.

Authors:  Sven O Dahms; John W M Creemers; Yvonne Schaub; Gleb P Bourenkov; Thomas Zögg; Hans Brandstetter; Manuel E Than
Journal:  Sci Rep       Date:  2016-09-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.